Jeffrey Hough

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Archana Anantharaman, Terence W. Friedlander, David Lu et al. · BMC Cancer · 2016 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +17

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer

Gayatri Premasekharan, Elizabeth Gilbert, Ross A. Okimoto et al. · Cancer Letters · 2016 · 27 citations

Medicine, Molecular Biology, Oncology +13

Evaluation of kangaroo pericardium as an alternative substitute for reconstructive cardiac surgery.

W. M. L. Neethling, Sue Cooper, J J Van Den Heever et al. · PubMed · 2002 · 17 citations

Engineering, Bioengineering, Cardiology +12

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study

Rahul Aggarwal, Alan H. Bryce, Charles J. Ryan et al. · Urologic Oncology Seminars and Original Investigations · 2017 · 13 citations

Medicine, Oncology, Pharmacology +15

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Archana Anantharaman, Terence W. Friedlander, David Lu et al. · Journal of Clinical Oncology · 2016 · 13 citations

Medicine, Immunology, Oncology +17